MAPT and Alzheimer disease: Plasma p-tau217 biomarkers have shown strong discriminative accuracy for AD, as well as strong relationships between amyloid and tau pathologies in several studies,11, 12, 13, 14 which suggests that p-tau217 has emerged as a strong candidate for future prospective clinical implementation studies.29